Collegium Pharmaceutical, Inc (COLL) · Aug 13, 2026 · Other events
$50M ASR — $50M commitment; 1.56M shares initially delivered
Collegium converts an existing $150M authorization into a $50M ASR, immediately taking in roughly 4.8% of outstanding shares.
The direction was already known: Collegium had a $150 million buyback authorization. The July 2025 program runs through December 31, 2026, so the market already had a standing expectation that excess cash could be returned through repurchases.
| Filing figure | Detail |
|---|---|
| ASR value | $50 million (ASR Agreement) |
| Initial shares delivered | 1,556,420 (ASR Agreement) |
| Initial shares as a share of 32.5M outstanding | ~4.8% (ASR Agreement) |
| Portion of the $150M authorization | One-third (ASR Agreement) |
| Expected final settlement | No later than Q4 2026 (ASR Agreement) |
The new information is execution, not a new capital-return strategy. Collegium is committing one-third of the authorization now and receiving roughly 80% of the expected shares upfront, based on the August 12 closing price of $25.70. The final share count will vary with the volume-weighted average price during the ASR term (ASR Agreement).
The net read is meaningful but not an expectation beat. The filing creates immediate share-count support and confirms management is willing to deploy cash, but it does not increase the previously authorized $150 million ceiling. With no earnings, guidance, or published market benchmark to beat, this is best classified as a partly anticipated buyback execution event rather than a surprise positive catalyst.
Final ASR settlement, no later than Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!